{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:39:03Z","timestamp":1792600743055,"version":"4.5.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Interferon alpha (IFN-\u03b1) is a fascinating molecule with many biological properties yet to be fully understood. Among these properties, several have demonstrated usefulness for targeting malignant cells, including hematopoietic cells from patients with myeloproliferative neoplasms. Indeed, IFN-\u03b1 has been used for decades across all myeloproliferative neoplasms, but only recently a new form, ropegIFN-\u03b12b, was approved to treat patients with polycythemia vera. Many phase 2 and more recently phase 3 studies have demonstrated IFN-\u03b1's promise in treating patients with essential thrombocythemia and early-stage myelofibrosis. In addition, although not approved in that situation, IFN-\u03b1 is the only cytoreductive therapy that can be used during pregnancy. Today, IFN-\u03b1 is a key medicine for polycythemia vera and essential thrombocythemia, while its place in the management of myelofibrosis must be better defined. The advantages of IFN therapy include a well-known safety profile, high rates of clinical and molecular responses, and a unique ability to deeply reduce the mutant allele burden of most of the driver mutations causing myeloproliferative neoplasms. Recent preliminary data from prospective studies suggest that molecular responses may be correlated with prolonged event-free survival, raising the hope that IFN therapy may ultimately alter the natural history of many diseases.<\/jats:p>","DOI":"10.1182\/hematology.2024000577","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:05:08Z","timestamp":1733497508000},"page":"535-540","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Pegylated interferon: the who, why, and how"],"prefix":"10.1182","volume":"2024","author":[{"given":"Jean-Jacques","family":"Kiladjian","sequence":"first","affiliation":[{"name":"Hopital Saint-Louis, Paris Cit\u00e9 University, Inserm CIC 1427, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"11","key":"2024121115504704800_hem2024000577C1","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in BCR-ABL-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"key":"2024121115504704800_hem2024000577C2","doi-asserted-by":"crossref","first-page":"606456","DOI":"10.3389\/fimmu.2020.606456","article-title":"Type I interferon (IFN)- regulated activation of canonical and non-canonical signaling pathways","volume":"11","author":"Mazewski","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"2024121115504704800_hem2024000577C3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/v16030364","article-title":"IFN\u03b1 subtypes in HIV infection and immunity","volume":"16","author":"Karakoese","year":"2024","journal-title":"Viruses"},{"issue":"3","key":"2024121115504704800_hem2024000577C4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2141.1994.tb08324.x","article-title":"The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera","volume":"87","author":"Castello","year":"1994","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2024121115504704800_hem2024000577C5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/stem.5530080718","article-title":"Sensitivity of erythroid progenitors to recombinant growth factors in the diagnosis of myeloproliferative disorders","volume":"8","author":"Dudley","year":"1990","journal-title":"Int J Cell Cloning"},{"issue":"4","key":"2024121115504704800_hem2024000577C6","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V70.4.1014.1014","article-title":"Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia","volume":"70","author":"Carlo-Stella","year":"1987","journal-title":"Blood"},{"issue":"2","key":"2024121115504704800_hem2024000577C7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2141.1994.tb04752.x","article-title":"Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha","volume":"86","author":"Messora","year":"1994","journal-title":"Br J Haematol"},{"issue":"8","key":"2024121115504704800_hem2024000577C8","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2002-07-2287","article-title":"Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin","volume":"101","author":"Liu","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2024121115504704800_hem2024000577C9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-018-0133-0","article-title":"Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo","volume":"8","author":"Verger","year":"2018","journal-title":"Blood Cancer J"},{"issue":"4","key":"2024121115504704800_hem2024000577C10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"},{"issue":"18","key":"2024121115504704800_hem2024000577C11","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2024121115504704800_hem2024000577C12","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2021010986","article-title":"Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms","volume":"138","author":"Mosca","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2024121115504704800_hem2024000577C13","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN\u03b1","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"issue":"8607","key":"2024121115504704800_hem2024000577C14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","article-title":"Recombinant interferon-alpha for treatment of polycythaemia vera","volume":"2","author":"Silver","year":"1988","journal-title":"Lancet"},{"issue":"8617","key":"2024121115504704800_hem2024000577C15","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0140-6736(88)92625-6","article-title":"Treatment of essential thrombocythaemia by alpha 2a interferon","volume":"2","author":"Bellucci","year":"1988","journal-title":"Lancet"},{"issue":"6","key":"2024121115504704800_hem2024000577C16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","article-title":"Efficacy and safety of pegylated-interferon \u03b1-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups","volume":"162","author":"Ianotto","year":"2013","journal-title":"Br J Haematol"},{"issue":"18","key":"2024121115504704800_hem2024000577C17","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1200\/JCO.2011.35.6238","article-title":"Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms","volume":"29","author":"Hasselbalch","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2024121115504704800_hem2024000577C18","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/j.clml.2020.05.018","article-title":"Interferon therapy in myelofibrosis: systematic review and meta-analysis","volume":"20","author":"Bewersdorf","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2024121115504704800_hem2024000577C19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","article-title":"Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis","volume":"35","author":"Bewersdorf","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2024121115504704800_hem2024000577C20","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"9","key":"2024121115504704800_hem2024000577C21","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk- stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"2024121115504704800_hem2024000577C22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, Version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2024121115504704800_hem2024000577C23","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"19","key":"2024121115504704800_hem2024000577C24","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024121115504704800_hem2024000577C25","doi-asserted-by":"crossref","first-page":"EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335","article-title":"Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera","volume":"2","author":"Barbui","year":"2023","journal-title":"NEJM Evid"},{"issue":"2","key":"2024121115504704800_hem2024000577C26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"Cassinat","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"2024121115504704800_hem2024000577C27","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2024121115504704800_hem2024000577C28","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00277-024-05665-4","article-title":"ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options","volume":"103","author":"Kiladjian","year":"2024","journal-title":"Ann Hematol"},{"issue":"24","key":"2024121115504704800_hem2024000577C29","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-\u03b1 may retard progression of early primary myelofibrosis: a preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2024121115504704800_hem2024000577C30","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2024121115504704800_hem2024000577C31","doi-asserted-by":"crossref","first-page":"e882","DOI":"10.1097\/HS9.0000000000000882","article-title":"Outcome of 129 pregnancies in polycythemia vera patients: a report of the European LeukemiaNET","volume":"7","author":"Wille","year":"2023","journal-title":"Hemasphere"},{"issue":"9","key":"2024121115504704800_hem2024000577C32","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood.2023020729","article-title":"How I treat myeloproliferative neoplasms in pregnancy","volume":"143","author":"Robinson","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2024121115504704800_hem2024000577C33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.26067","article-title":"Myeloproliferative neoplasms and pregnancy: overview and practice recommendations","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"key":"2024121115504704800_hem2024000577C34","unstructured":"Drugs and Lactation Database (LactMed\u00ae). Interferon alfa. Accessed 23September2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500992\/."},{"issue":"8","key":"2024121115504704800_hem2024000577C35","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2024121115504704800_hem2024000577C36","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"issue":"19","key":"2024121115504704800_hem2024000577C37","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024121115504704800_hem2024000577C38","article-title":"JAK2V617F molecular response correlates with event-free survival in an early polycythemia vera population","author":"Kiladjian","year":"2024"},{"issue":"suppl 1","key":"2024121115504704800_hem2024000577C39","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood-2023-185108","article-title":"Impact of cytoreductive drugs upon outcomes in a contemporary cohort of adolescent and young adults with essential thrombocythemia and polycythemia vera","volume":"142","author":"Beauverd","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121115504704800_hem2024000577C40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-141223","article-title":"Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission","volume":"136","author":"Daltro De Oliveira","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2024121115504704800_hem2024000577C41","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201268","article-title":"JAK2V617F myeloproliferative neoplasm eradication by a novel interferon\/arsenic therapy involves PML","volume":"218","author":"Dagher","year":"2021","journal-title":"J Exp Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/535\/2346495\/535kiladjian.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/535\/2346495\/535kiladjian.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:20:46Z","timestamp":1733948446000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/535\/526195\/Pegylated-interferon-the-who-why-and-how"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000577","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}